Bain Capital Life Sciences buys $1.7m in Olema Prescribed drugs inventory

Bain Capital Life Sciences Buyers, LLC, a major stakeholder in Olema Prescribed drugs, Inc. (NASDAQ:OLMA), just lately bought 300,000 shares of the corporate’s frequent inventory. The acquisition, accomplished on January 8, 2025, was made at a weighted common worth of $5.7579 per share, amounting to a complete funding of roughly $1.73 million. The acquisition comes as OLMA trades close to its 52-week low of $4.93, with the inventory down over 59% prior to now six months. In line with InvestingPro information, analysts preserve a powerful purchase consensus on the inventory, with worth targets starting from $20 to $30.

Following this transaction, Bain Capital Life Sciences holds 7,800,000 shares of Olema Prescribed drugs, representing a good portion of the corporate’s $359 million market capitalization. The transaction underscores Bain Capital’s continued curiosity in Olema Prescribed drugs, additional solidifying its place as a serious shareholder within the firm. Whereas the inventory reveals excessive volatility, InvestingPro evaluation reveals the corporate maintains a powerful steadiness sheet with additional cash than debt. Subscribers can entry 11 extra ProTips and detailed monetary metrics for deeper insights into OLMA’s funding potential.

In different latest information, Olema Prescribed drugs disclosed an unregistered alternate of fairness securities in a latest SEC submitting, involving the alternate of frequent inventory for pre-funded warrants with three vital funding entities. The entities embrace Bain Capital Life Sciences Alternatives IV, L.P., entities affiliated with Paradigm BioCapital Worldwide Fund Ltd., and entities affiliated with BVF Companions L.P.

The corporate has been the topic of a number of optimistic analyst scores following updates on scientific research information and promising preclinical findings. H.C. Wainwright reaffirmed its Purchase ranking for Olema Prescribed drugs, citing vital upside potential primarily based on the up to date scientific research information from the Section 1b/2 research of palazestrant mixed with ribociclib for treating metastatic breast most cancers.

TD Cowen additionally reiterated a Purchase ranking, inspired by the Scientific Profit Fee from a Section II trial involving palbociclib and ribociclib. Jefferies maintained a Purchase ranking as effectively, highlighting the potential of the corporate’s KAT6 inhibitor, OP-3136, which confirmed superior in vivo efficacy in comparison with Pfizer (NYSE:PFE)’s competing KAT6 inhibitor.

Goldman Sachs maintained its Purchase ranking on Olema Prescribed drugs, following the presentation of preclinical information for OP-3136 on the EORTC-NCI-AACR Symposium. The research demonstrated OP-3136’s anti-tumor exercise, displaying additional enchancment when used with endocrine remedy and CDK4/6 inhibitors. These are latest developments shaping the investor sentiment round Olema Prescribed drugs.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.